On March 9, 2017 Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, reported that M. Scott Maguire, Xenetic’s Chief Executive Officer will present at the 29th Annual ROTH Conference on Tuesday, March 14th at 11:30 a.m. PT in Dana Point, CA (Press release, Xenetic Biosciences, MAR 9, 2017, View Source [SID1234537804]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During his presentation, Mr. Maguire will provide a corporate update and will discuss the Company’s license deal with Shire plc (LSE: SHP, NASDAQ: SHPG), a significant stockholder of the Company, along with the clinical status of the product candidate PSA-Recombinant SHP656 (Factor VIII) being developed as a long-acting therapeutic for the treatment of hemophilia utilizing Xenetic’s proprietary PolyXen platform technology. Xenetic has the potential to receive from Shire up to $100 million in cash milestones plus royalties linked to sales.

Mr. Maguire will also discuss the Company’s clinical and regulatory progress for its in-house product candidate, XBIO-101 (sodium cridanimod), currently in development for the treatment of progesterone resistant endometrial cancer.

A live webcast of the presentation will be available by accessing the IR Calendar in the Investors section of Xenetic’s website (www.xeneticbio.com). A replay of the webcast will be available for 90 days, starting approximately two hours after the presentation ends.

On March 8, 2017 Xynomic Pharmaceuticals has acquired Greater China rights to a novel ACAT-1 inhibitor for cancer indications from Resarci Therapeutics of West Lafayette, Indiana (Press release, Xynomic Pharmaceuticals, MAR 8, 2017, View Source [SID1234535672]). It will be tested as a treatment for prostate, pancreatic and other solid tumors. Xynomic will pay $1.2 million in upfront and milestone payments, plus royalties that could total $59 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Filing, Annual, AstraZeneca, 2016, MAR 7, 2017, View Source [SID1234518031])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 8, 2017 Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) reported that it has launched new generic oxycodone extended release formulations to treat sustained cancer pain: Oxycodone Extended Release 5 mg, 10 mg, 20 mg and 40 mg "Daiichi Sankyo" (date of approval: August 15, 2016; date of listing in the NHI reimbursement price list in Japan: December 9, 2016) (Press release, Daiichi Sankyo, MAR 7, 2017, View Source [SID1234518076]).

This oxycodone extended release tablet is an opioid analgesic providing the degree of analgesia prescribed for various cancers with moderate to severe pain, and the first tablet generic for an oxycodone extended release formulation. Our domestic subsidiary, Daiichi Sankyo Propharma Co., Ltd. (manufacturing and marketing) manufactures from drug substance to formulation using our GWATab technology*.

Daiichi Sankyo expects this drug to be able to contribute to all patients and medical staff by offering a new therapeutic option.

Product summary
Product name
Therapeutic Category
Original brand name
Oxycodone Extended Release tablets 5mg "Daiichi Sankyo"
Oxycodone Extended Release tablets 10mg "Daiichi Sankyo"
Oxycodone Extended Release tablets 20mg "Daiichi Sankyo"
Oxycodone Extended Release tablets 40mg "Daiichi Sankyo"
Sustained cancer pain treatment
OxyContinⓇTablets 5mg
OxyContinⓇTablets 10mg
OxyContinⓇTablets 20mg
OxyContinⓇTablets 40mg

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

*GWATab (Gelling WAter soluble polymer matrix Tablet) technology is proprietary technology that combines a drug substance with a water-soluble polymer, releasing medication along a wide range of the gastrointestinal tract after dosing, for sustained drug efficacy.

On March 07, 2017 Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the discovery and development of novel drug candidates based on proprietary macrocyclic chemistry and The Hospital for Sick Children (SickKids), one of the world’s premier biomedical research and treatment centres, reported they have entered into a research agreement designed to discover novel modulators for multiple new and existing biological targets of pharmacological interest across a variety of disease areas, including cardiovascular, immunology and oncology (Press release, Cyclenium, MAR 7, 2017, View Source [SID1234635927]). This collaboration will provide SickKids researchers with immediate access to Cyclenium’s proprietary QUEST Library of next generation macrocyclic molecules and associated chemical hit and lead optimization capabilities. The initial objective of these exploratory efforts is to identify compounds capable of interacting with specific therapeutic targets being studied at SickKids, thereby providing tools to improve the understanding of their involvement in the pathophysiology of specific diseases, with the ultimate goal of discovering novel therapeutic or diagnostic agents.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted that a distinguished institution like SickKids is interested in the power and capabilities of our small molecule macrocyclic technology to contribute to their cutting-edge research efforts," stated Helmut Thomas, Ph.D., President, Chief Scientific Officer & Chief Executive Officer of Cyclenium. "The combination of their internationally renowned investigators and translational expertise with our CMRT Technology and past development success in the macrocycle space provides unique opportunities for the ground-breaking discovery and development of new therapies and diagnostics."

The library will be made available to researchers through the SickKids Proteomics, Analytics, Robotics & Chemical Biology Centre (SPARC BioCentre). The SPARC BioCentre is a high-throughput drug screening facility at SickKids. One of the first studies to be initiated involves targets implicated for the treatment of cancer and immune disorders.

For Cyclenium, this is the latest in an extensive series of international discovery collaborations established with prominent companies and research institutions to explore the exciting potential of its unique macrocycle chemistry technology, including Astellas Pharma, Haplogen GmbH, Fundación MEDINA, German Cancer Research Center (DKFZ), McGill University/Goodman Cancer Research Centre, Institute for Research in Immunology and Cancer (IRIC)/Université de Montréal, and Southern Research Institute.